IONIQ Sciences / Awards and Recognition  / IONIQ is “Platform of the Year 2023”

IONIQ is “Platform of the Year 2023”

Salt Lake City, UT, April 13, 2023 – We are honored to announce that we have been recognized as the “Platform of the Year 2023” by Global 100 and EMG Publishing. This is a testament to our team’s ability to harness the power of non-invasive bioimpedance to dramatically improve early-stage cancer detection.

INNOVATIVE: The body’s electrical properties change in the presence of cancer and our digital platform that’s on-track to be the first FDA-cleared use of bioimpedance to detect those changes in lung cancer. Our first planned-product will be in lung cancer, which the FDA already designated a ‘Breakthrough Device.’ Then breast cancer where we’ve already published promising early feasibility results (IEEE journal). And then GI cancers.

NON-INVASIVE: In just 20min, you could know your risk of cancer with no needles, no radiation and no surgery.

LUNG CANCER TESTING SOLUTION: Our solution to the world’s deadliest cancer is to catch it early, when treatment is most effective, potentially increasing 5-year survivability from 10% to 90%.


About Global 100 and EMG Publishing
The ambition of the Global 100 annual awards program is to recognize the achievements and expertise of firms and individuals operating to the highest standards across the globe. By highlighting and publicizing the accomplishments of business leaders and professionals, we aim to inform and inspire our readership base, which consists of over 376,000 CEOs, CFOs, legal, accounting and media professionals worldwide. Click here to read more.

About IONIQ Sciences, Inc.
IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics (EIA) or bioimpedance technology and Artificial Intelligence (AI). IONIQ Science’s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA.

About BioHive
IONIQ Sciences is proud to be a key supporter and member of the newly formed BioHive, a collective representing the life science and healthcare innovation ecosystem. By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America and their innovations are improving the lives of millions of patients. To learn more, please visit:

For further information about IONIQ Sciences, Inc., please contact:
Andy Robertson | 1-801-736-0729 |
IONIQ Sciences, Vice President of Business Development

IONIQ Sciences, Inc.
350 W. 800 N., Suite 214
Salt Lake City, Utah 84103

Follow IONIQ Sciences, Inc. on TwitterFacebook, Instagram and LinkedIn: @IONIQSciences